Phendimetrazine Tartrate Ext-Rel Capsules CIII
Generic Name and Formulations:
Phendimetrazine tartrate 105mg; ext-rel caps.
Indications for Phendimetrazine Tartrate Ext-Rel Capsules:
Management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of ≥30kg/m2 or ≥27kg/m2 in the presence of other risk factors (eg, controlled hypertension, diabetes, hyperlipidemia) who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone.
≥17yrs: 1 cap in the AM (30–60 minutes before morning meal).
<17yrs: not recommended.
History of cardiovascular disease (eg, coronary artery disease, stroke, arrhythmias, CHF, uncontrolled hypertension, pulmonary hypertension). Hyperthyroidism. Glaucoma. Agitated states. History of drug abuse. Pregnancy (Cat.X). Nursing mothers. Concomitant other CNS stimulants, anorectic agents. During or within 14 days of MAOIs.
Increased risk of pulmonary hypertension with repeated courses. Heart murmer, valvular heart disease: not recommended. Do not exceed max recommended dose. Obtain baseline cardiac evaluation prior to initiating therapy to detect pre-existing valvular heart disease or pulmonary hypertension. Mild hypertension. Diabetes. Prescribe minimal supply to avoid overdose. Renal impairment. Elderly.
Phenylalkylamine sympathomimetic amine.
See Contraindications. Hypertensive crisis with MAOIs. Anorectic agens use within prior year: not recommended. Insulin and oral hyperglycemic requirements may be altered. May decrease hypotensive effect of guanethidine, adrenergic neuron blocking drugs. Concomitant alcohol may result in adverse drug reaction.
Primary pulmonary hypertension and/or regurgitant cardiac valvular disease, palpitation, tachycardia, elevated BP, ischemic events, overstimulation, restlessness, insomnia, agitation, flushing, tremor, sweating, dizziness, headache, psychotic state, blurred vision, dry mouth, GI upset, constipation, stomach pain, urinary frequency, dysuria, changes in libido; tolerance (discontinue when occurs), withdrawal effects (w. prolonged use).
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Cochrane Data Release and the Case for "Open Science"
- Rates of Incident Type 2 Diabetes in Chronic Kidney Disease
- Characteristics of Acquired Partial Lipodystrophy With Metabolic Abnormalities
- Poor Glycemic Control Associated With Higher Risk for Dementia in Older Adults With T1D
- Shift Seen From EDs to Urgent Care for Low-Acuity, Acute Care